2020
DOI: 10.1016/j.abb.2019.108241
|View full text |Cite
|
Sign up to set email alerts
|

The effects of iron overload on mitochondrial function, mitochondrial dynamics, and ferroptosis in cardiomyocytes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
59
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 88 publications
(62 citation statements)
references
References 47 publications
2
59
0
Order By: Relevance
“…The precise mechanism of the beneficial effects of liproxstatin-1 on mitochondria involves the reduction of VDAC1 level and its oligomerization, without affecting VDAC2/3, as well as a decrease in mitochondrial ROS production by the ETC complex I (NADH:ubiquinone oxidoreductase). These results are in agreement with studies postulating that mitochondrial ROS generation is a significant contributor to ferroptosis [ 105 , 106 ]. This contrasts with the often-represented standpoint that mitochondrial damage is a secondary event in ferroptosis [ 13 , 80 ] and also opposes studies that did not observe changes in complex I ROS production in erastin-induced or ferrostatin-inhibited ferroptosis [ 12 , 63 ], suggesting that the impact of mitochondrial ROS on ferroptosis might be dependent on the specific inducer or inhibitor of ferroptosis used.…”
Section: Mitochondria and Ferroptosis In Cardiovascular Diseasessupporting
confidence: 93%
“…The precise mechanism of the beneficial effects of liproxstatin-1 on mitochondria involves the reduction of VDAC1 level and its oligomerization, without affecting VDAC2/3, as well as a decrease in mitochondrial ROS production by the ETC complex I (NADH:ubiquinone oxidoreductase). These results are in agreement with studies postulating that mitochondrial ROS generation is a significant contributor to ferroptosis [ 105 , 106 ]. This contrasts with the often-represented standpoint that mitochondrial damage is a secondary event in ferroptosis [ 13 , 80 ] and also opposes studies that did not observe changes in complex I ROS production in erastin-induced or ferrostatin-inhibited ferroptosis [ 12 , 63 ], suggesting that the impact of mitochondrial ROS on ferroptosis might be dependent on the specific inducer or inhibitor of ferroptosis used.…”
Section: Mitochondria and Ferroptosis In Cardiovascular Diseasessupporting
confidence: 93%
“…As shown in Figure 2, the changes in mitochondrial dynamics are associated with cell viability, apoptosis, and bioenergetic adaptations [75,76]. Mitochondrial fission is observed when mitochondria are subjected to oxidative stress-induced damage and segregates damaged mitochondria from the normal ones [77][78][79][80]. The mitochondrial fusion-fission balance is disrupted by intracellular and extracellular stress, and the fragmented mitochondria form small spheres or short rods in comparison to extensive elongated network of the normal mitochondria [20,81].…”
Section: Mitochondrial Fissionmentioning
confidence: 99%
“…It is characterized by the accumulation of lipid peroxidation products and lethal ROS derived from iron metabolism and can be pharmacologically inhibited by iron chelators. Although the detailed mechanism by which iron overload promotes ferroptosis has yet to determined, it is reasonable to hypothesize that iron overload may drive the generation of hydroxyl radicals, which further react with liposomes to produce lipid peroxidation products and cause mitochondrial dysfunction, and eventually ferroptosis [ 310 , 311 , 312 ]. Although mitochondria have been shown to be vital regulators of iron homeostasis and ferroptosis in neurodegenerative diseases [ 313 ], more direct evidence targeting iron overload, mitochondrial dysfunction, and ferroptosis is still required.…”
Section: Molecular Mechanisms Of Metal-induced Mitochondrial Dysfunctionmentioning
confidence: 99%